- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07690124
S-Acetyl Glutathione and Performance Recovery in Soccer
Pharmacodynamics & Pharmacokinetics Study of S-Acetyl Glutathione in Highly Trained Soccer Players
Przegląd badań
Status
Warunki
Szczegółowy opis
Following baseline testing [including assessment of anthropometrics, body composition (via DXA instrumentation) and physical performance (cardiorespiratory fitness, drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque)], 20 well-trained, soccer players will participate in three trials, receiving daily (i) 200 mg SAG, (ii) 500 mg SAG or (iii) Placebo, according to a randomized, double-blind, crossover, repeated-measures design. The duration of each trial will be 11 days, including a 7-day pre-loading period (days 1 -7), a match day (day 8) and 3 consecutive recovery days after the match (days 9-11). Between trials a 3-week washout period will be implemented.
Pre-loading period: During the 7-day pre-loading period players will participate daily in training sessions according to a soccer-specific weekly training schedule, while receiving the respective supplement. Blood samples will be collected on day 1 and day 7 while daily nutrient intake (via 7-day diet recalls), physical activity level (via accelerometry) and training load (via global positioning system instrumentation during training sessions) will be monitored daily.
Match day: On match day, players will participate in an official 90-min soccer match. Field activity (total distance, average and maximum speed, high intensity running, high speed running, accelerations, decelerations) and heart rate (mean and maximum heart rate) will be continuously monitored using global positioning system (GPS) and heart rate monitors, respectively.
Recovery days: During the 3-day recovery period after the match, players will participate daily in (i) morning testing sessions and (ii) training sessions in the evening. Testing sessions will include blood sampling and performance measurements including drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque and muscle soreness (DOMS). Dietary intake (via a 3-day diet recalls), physical activity level (via accelerometry) and training load (via GPS instrumentation during training sessions) will be monitored daily.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Dimitrios Draganidis, PhD
- Numer telefonu: +30 2431047078
- E-mail: ddraganidis@uth.gr
Kopia zapasowa kontaktu do badania
- Nazwa: Athanasios Poulios, PhD
- Numer telefonu: +30 2431047053
- E-mail: athanpoul@gmail.com
Lokalizacje studiów
-
-
Karies
-
Trikala, Karies, Grecja, 42100
- Department of Physical Education and Sport Science, University of Thessaly
-
Kontakt:
- Ioannis G Fatouros, PhD
- Numer telefonu: +30 2431047047
- E-mail: ifatouros@uth.gr
-
Kontakt:
- Athanasios Z Jamurtas, PhD
- Numer telefonu: +30 24310 47054
- E-mail: ajamurt@uth.gr
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- participation at elite (top three division leagues) for ≥ 4 years
- no recent history of febrile illness, musculoskeletal problems and metabolic diseases
- no consumption of medications and performance-enhancing supplements (including anti-inflammatory, antioxidants, vitamins and multivitamin supplements) for at least 6 months prior to the study
- participation in at least 5 training sessions and 1 match per week
- non-smokers
Exclusion Criteria:
- musculoskeletal injury
- consumption of medication and performance-enhancing supplements
- illness during the course of the study
- loss of follow-up measurements
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: SAG-200 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 200 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
Eksperymentalny: SAG-500 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 500 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
Komparator placebo: Placebo Trial
Oral administration of placebo
|
Participants will be supplemented daily with placebo, orally, over the 11-day experimental period.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in creatine kinase levels
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Creatine kinase concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in myoglobin levels
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Myoglobin concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in reduced glutathione
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Reduced glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in oxidized glutathione
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Oxidized glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione reductase activity
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Glutathione reductase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione peroxidase activity
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11.
|
Glutathione peroxidase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11.
|
|
Change in catalase activity
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Catalase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in superoxide dismutase activity
Ramy czasowe: Day 1, day 7, day 9, day 10 and day 11
|
Superoxide dismutase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in maximal voluntary isometric contraction
Ramy czasowe: Day 1, day 9, day 10 and day 11
|
Maximal voluntary isometric contraction will be assessed at a 60o knee joint angle, in both dominant and non-dominant limb, using an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in maximal peak torque
Ramy czasowe: Day 1, day 9, day 10 and day 11
|
Maximal concentric and eccentric peak torque at 60o/s of the knee extensors and flexors in both dominant and non-dominant limb, will be assessed on an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in jumping performance
Ramy czasowe: Day 1, day 9, day 10 and day11
|
Countermovement jump and drop jump performance will be tested using an optical measurement system consisting of a transmitting and receiving bar
|
Day 1, day 9, day 10 and day11
|
|
Change in repeated sprint ability
Ramy czasowe: Day 1, day 9, day 10 and day 11
|
Repeated sprint ability will be assessed by performing 5x25 m sprints interspersed by a 25-seconds recovery period using infrared photocells
|
Day 1, day 9, day 10 and day 11
|
|
Change in delayed onset muscle soreness (DOMS)
Ramy czasowe: Day 1, day 9, day 10 and day 11
|
DOMS will be assessed using a 10-scale visual analogue scale
|
Day 1, day 9, day 10 and day 11
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in total distance covered
Ramy czasowe: Daily throughout the 11-day experimental period
|
Total distance (km) covered during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in internal load
Ramy czasowe: Daily throughout the 11-day experimental period
|
Heart rate during training sessions and the match will be monitored using heart rate monitors
|
Daily throughout the 11-day experimental period
|
|
Change in dietary intake
Ramy czasowe: Daily throughout the 11-day experimental period
|
Dietary intake will be assessed using diet recalls
|
Daily throughout the 11-day experimental period
|
|
Change in time spent in moderate-to-vigorous physical activity
Ramy czasowe: Daily throughout the 11-day experimental period
|
The time (minutes) spent in moderate-to-vigorous physical activity on a daily basis will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with high-intensity running
Ramy czasowe: Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity running during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with sprinting
Ramy czasowe: Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity sprinting during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in accelerations
Ramy czasowe: Daily throughout the 11-day experimental period
|
The number of accelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in decelerations
Ramy czasowe: Daily throughout the 11-day experimental period
|
The number of decelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in total step count
Ramy czasowe: Daily throughout the 11-day experimental period
|
The total number of steps performed daily will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in physical activity-related energy expenditure
Ramy czasowe: Daily throughout the 11-day experimental period
|
Energy expenditure (kcal) related to habitual physical activity will be assessed using accelerometers
|
Daily throughout the 11-day experimental period
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Dimitrios Draganidis, PhD, University of Thessaly, Department of Physical Education and Sport Science
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- UTH-06/13.02.2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na 200 mg S-Acetyl Glutathione
-
ShionogiZakończony
-
Dr. Chris McGlory, PhDIovate Health Sciences International IncZakończony
-
Haudongchun Co., Ltd.NieznanyBakteryjne zapalenie pochwy | HUDC_VT | HaudongchunRepublika Korei
-
JW PharmaceuticalZakończonyZaburzenie erekcjiRepublika Korei
-
Mylan Pharmaceuticals IncZakończonyZdrowyStany Zjednoczone
-
Novelfarma Ilaç San. ve Tic. Ltd. Sti.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiZakończony
-
Ascletis Pharmaceuticals Co., Ltd.Ascletis Pharmaceuticals Co., Ltd.ZakończonyZaawansowane guzy liteStany Zjednoczone
-
Novartis PharmaceuticalsZakończonyNiedrobnokomórkowy rak płucIndie
-
ShionogiZakończonyAtopowe zapalenie skóryStany Zjednoczone